Rivaroxaban Tablet, Film Coated
Product Images NDC 72205-416

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Rivaroxaban (NDC 72205-416). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rivaroxaban-tabs-2-5-mg-180s-cntr-lbl (Rivaroxaban Tabs 2 5 mg 180s Cntr Lbl)

Label for Rivaroxaban Tablets USP 2.5 mg, film-coated oral tablets. The label states 180 tablets per container and includes storage instructions. Manufactured by MSN Laboratories Private Limited, India, and distributed by Novadoz Pharmaceuticals LLC, Piscataway, NJ. The label features a barcode and a note for pharmacists to dispense the medication guide.*

FDA Label Image

Rivaroxaban-tabs-2-5-mg-30s-cntr-lbl (Rivaroxaban Tabs 2 5 mg 30s Cntr Lbl)

Label for Rivaroxaban Tablets, USP 2.5 mg, film-coated oral tablets. The label indicates a package size of 30 tablets and directs pharmacists to dispense an accompanying Medication Guide. Manufactured by MSN Laboratories in India and distributed by Novadoz Pharmaceuticals LLC, Piscataway, NJ. It includes storage instructions and barcode information.*

FDA Label Image

Rivaroxaban-tabs-2-5-mg-60s-cntr-lbl (Rivaroxaban Tabs 2 5 mg 60s Cntr Lbl)

Label for Rivaroxaban Tablets USP, 2.5 mg film-coated oral tablets. The label shows a package size of 60 tablets, manufactured by MSN Laboratories Private Limited (India) and distributed by Novadoz Pharmaceuticals LLC (Piscataway, NJ). It includes storage instructions and a bar code, with the product marked as Rx only.*

FDA Label Image

Rivaroxaban-tabs-2-5-mg-blister-crtn-lbl (Rivaroxaban Tabs 2 5 mg Blister Crtn Lbl)

Packaging label for Rivaroxaban Tablets USP, 2.5 mg per tablet, film-coated oral tablets. The label indicates a package containing 100 tablets in 10 blister strips of 10 tablets each. Distributed by Novadoz Pharmaceuticals LLC and manufactured by MSN Laboratories Private Limited in India. The label includes storage instructions and a reminder for pharmacists to dispense the accompanying Medication Guide.*

FDA Label Image

Rivaroxaban-tabs-2-5-mg-blister-foil-lbl (Rivaroxaban Tabs 2 5 mg Blister Foil Lbl)

Rivaroxaban 2.5 mg film-coated tablets packaging label from Novadoz Pharmaceuticals LLC. The label includes multiple identical sections each showing the product name, strength, dosage form, bar code, lot and expiration placeholders, and the manufacturer details. It is intended for a carton or blister pack with tear and peel instructions.*

FDA Label Image

Rivaroxaban-tabs-fig-10 (Rivaroxaban Tabs Fig 10)

A cumulative incidence rate line graph comparing Rivaroxaban and placebo over days from randomization up to 1095 days. The y-axis represents cumulative incidence rate (%) and the x-axis shows days from randomization with the number of subjects at risk at various time points listed below. The graph includes a hazard ratio comparison of 0.74 (95% CI: 0.65–0.86) for Rivaroxaban versus placebo.*

FDA Label Image

Rivaroxaban-tabs-fig-11 (Rivaroxaban Tabs Fig 11)

A line graph depicting cumulative incidence rates (%) over days from randomization comparing Rivaroxaban and Placebo treatment groups. The x-axis shows days from 0 to 1095, and the y-axis shows cumulative incidence rate from 0% to 25%. The graph includes a legend distinguishing Rivaroxaban (solid line) from Placebo (dashed line) and a table below indicating the number of subjects at risk at various time points for each group.*

FDA Label Image

Rivaroxaban-tabs-fig-12 (Rivaroxaban Tabs Fig 12)

A forest plot comparing the primary efficacy outcome rates per year between Rivaroxaban and placebo across subgroups by age, sex, weight, eGFR, baseline diabetes, CAD, randomization strata, clopidogrel use, history of revascularization, and critical limb ischemia categories. The plot includes hazard ratios with 95% confidence intervals depicting relative risk favoring either Rivaroxaban or placebo.*

FDA Label Image

Rivaroxaban-tabs-fig-2 (Rivaroxaban Tabs Fig 2)

A pharmacokinetic chart showing fold change and 90% confidence intervals for Cmax and AUC of rivaroxaban in various populations including end-stage renal disease, renal impairment (severe, moderate, mild), age groups, body weight categories, and hepatic impairment. The x-axis represents change relative to reference from 0.5 to 3.1.*

FDA Label Image

Rivaroxaban-tabs-fig-3 (Rivaroxaban Tabs Fig 3)

A chart showing the fold change in pharmacokinetic parameters Cmax and AUC relative to rivaroxaban alone for various interacting drugs. The drugs are categorized under Combined P-gp and Strong CYP3A Inhibitors, Combined P-gp and Moderate CYP3A Inhibitor, Moderate CYP3A Inhibitor, Combined P-gp and Strong CYP3A Inducer, and Other Drugs, with corresponding fold change values and 90% confidence intervals plotted on a logarithmic scale.*

FDA Label Image

Rivaroxaban-tabs-fig-9 (Rivaroxaban Tabs Fig 9)

A forest plot comparing the efficacy outcomes of Rivaroxaban versus placebo, showing hazard ratios (HR) and 95% confidence intervals (CI) across multiple subgroups including age, sex, region, weight, estimated glomerular filtration rate (eGFR), myocardial infarction history, stroke history, heart failure history, baseline diabetes, and peripheral artery disease (PAD). The plot illustrates relative risk reductions favoring Rivaroxaban in most categories.*

FDA Label Image

Rivaroxaban-tabs-struture (Rivaroxaban Tabs Struture)

Chemical structure of rivaroxaban depicted as a molecular diagram showing its specific atoms and bonds. This structure corresponds to the active ingredient in the Rivaroxaban 2.5 mg film-coated oral tablet by Novadoz Pharmaceuticals LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.